Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD).
Verve Therapeutics will be responsible for advancing the research and development of the Lp(a) programme by completing Phase I clinical development.
Lilly will handle the subsequent development, manufacture and commercialisation activities of the programme.
Verve Therapeutics stated that elevated Lp(a) is a genetically validated, independent risk factor for aortic stenosis, ASCVD, thrombosis and ischaemic stroke.
The company will receive a combined upfront payment and equity investment of $60m.
It will also be entitled to receive research, development and commercial milestones of up to $465m, along with tiered royalties on global net sales of the product.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataLilly will provide funding for the Phase I clinical trials.
Verve Therapeutics will obtain the opt-in right to co-fund and share the potential margins on the Lp(a) programme across the world.
Verve Therapeutics co-founder and CEO Sekar Kathiresan stated: “Lp(a) is validated as one of [the] key drivers [of ASCVD], and as such, this programme represents another important step in our efforts to transform care.
“Blood concentrations of Lp(a) are determined almost entirely by inheritance. Unfortunately, lifestyle and currently approved lipid-lowering therapies have minimal to no impact.
“In patients with established ASCVD and elevated blood Lp(a), we believe there is a substantial opportunity for a single-course gene editing medicine to permanently lower Lp(a) levels, and we are thrilled to have joined forces with Lilly, an industry leader in cardiometabolic disease, to accelerate this programme toward patients.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
